Clinical trial · Interventional
Theranostic Applications of Radionuclides in Prostate Cancer
ACP3 Targeted -PET/ CT in Prostate Cancer
NCT07559201CI-TRIAL-00109889recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer (Diagnosis) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ACP3 PET/CT
- description
- Each subject receives a single intravenous injection of radiolabeld ACP3 and undergoes PET/CT imaging within the specified time.
- interventionNames
- Diagnostic Test: standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT
Primary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- 3 year
- description
- The sensitivity, specificity, and accuracy of standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
Secondary outcomes (2)
- measure
- Number of lesions
- timeFrame
- 3 year
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report); * Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.